MDdatacor Surpasses One Million Cardiology Patient Milestone; Database Doubles in Size over Last...

Health/Medical Writers

CHICAGO--(BUSINESS WIRE)--March 31, 2003

MDdatacor, inc. announced today at the 52nd Annual Scientific Sessions of the American College of Cardiology (ACC), that it has accumulated longitudinal medical data on more than one million individual cardiology

MDdatacor now receives routine medical information uploads from more than 50 cardiology practices representing approximately 900 cardiologists nationwide. Patients in these practices benefit because their cardiologists, using MDdatacor's technology, can more accurately identify appropriate chronically ill patients for new clinical trials, as well as life-saving and life-extending therapies.

"I am pleased with the acceleration in the growth rate of our database, becoming not just the largest but also the fastest growing," commented Blake Whitney, MDdatacor chairman, president and chief executive officer. "This is a clear result of our success in attracting large, prestigious groups into our Practice Network. Obviously, leading cardiologists see our value in helping them deliver quality care."

Physician practices provide MDdatacor with electronic copies of patient chart information, such as transcribed progress notes, lab results and demographic information. MDdatacor uses a patent-pending technology to convert this information into a single clinical database from which its Practice Network can identify patients who qualify for clinical trials or may be medically indicated for a new drug or device. Pharmaceutical and medical device companies contract with MDdatacor to help Network Practices find patients who are candidates for their clinical trials and new products, thus accelerating their product development timeline and increasing utilization of their products and services.

"The most frequently stated cause of trial delays is patient recruitment," commented John J. Needham, Senior Director, Johnson & Johnson Pharmaceutical Research and Development, LLC. and chairperson of the upcoming Drug Information Association symposium "Advances in Patient Enrollment, Adherence and Retention in Clinical Trials."

"Every day a drug is delayed getting to market costs the manufacturer well over $1 million in lost potential revenue. Innovative companies like MDdatacor can provide study sponsors with a very compelling option for accelerating trial enrollment by quickly and accurately identifying the potential participants for a clinical trial," said Needham.

About MDdatacor, inc.

Headquartered in Atlanta, Georgia, MDdatacor, through long-term contractual relationships with physicians and proprietary insight into their patient populations, accelerates physician utilization of new or improved therapeutic solutions and streamlines recruiting of candidates for clinical trials.

MDdatacor provides practices with decision support tools that improve clinical outcomes and enhance the practice's ability to conduct clinical research. For industry, MDdatacor enables clinical trial sponsors to identify optimal investigator sites and subsequently accelerate the trial screening and enrollment process, reducing the time and cost of new product development. MDdatacor also finds candidates for approved therapies, benefiting the manufacturer by increasing product utilization, the physician through improved compliance with clinical guidelines and the patient by improving access to potentially life-saving treatments. Please visit www.mddatacor.com for more information.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to economic, competitive, governmental and technological factors affecting the Company's operations, markets, services and related products, prices and other factors.